Immunogen Inc (DELISTED) (IMGN:DL)
31.23
0.00 (0.00%)
USD |
NASDAQ |
Feb 13, 16:00
Immunogen Cash from Financing (Quarterly): 32.13M for Sept. 30, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | 32.13M |
| June 30, 2023 | 437.56M |
| March 31, 2023 | 0.039M |
| December 31, 2022 | 26.07M |
| September 30, 2022 | 0.449M |
| June 30, 2022 | 0.411M |
| March 31, 2022 | 0.62M |
| December 31, 2021 | 279.23M |
| September 30, 2021 | 41.39M |
| June 30, 2021 | 0.344M |
| March 31, 2021 | 34.78M |
| December 31, 2020 | 97.21M |
| September 30, 2020 | 0.129M |
| June 30, 2020 | 0.423M |
| March 31, 2020 | 97.98M |
| December 31, 2019 | 2.062M |
| September 30, 2019 | 0.073M |
| June 30, 2019 | 0.67M |
| March 31, 2019 | 0.068M |
| December 31, 2018 | 1.358M |
| September 30, 2018 | 0.096M |
| June 30, 2018 | 163.10M |
| March 31, 2018 | 2.259M |
| December 31, 2017 | 101.93M |
| September 30, 2017 | -1.352M |
| Date | Value |
|---|---|
| June 30, 2017 | 0.032M |
| March 31, 2017 | |
| September 30, 2016 | |
| June 30, 2016 | 96.79M |
| March 31, 2016 | 0.188M |
| December 31, 2015 | 0.329M |
| September 30, 2015 | 4.462M |
| June 30, 2015 | 197.13M |
| March 31, 2015 | 0.116M |
| December 31, 2014 | 1.172M |
| September 30, 2014 | 0.144M |
| June 30, 2014 | 0.579M |
| March 31, 2014 | 1.502M |
| December 31, 2013 | 3.03M |
| September 30, 2013 | 4.025M |
| June 30, 2013 | 1.808M |
| March 31, 2013 | 1.367M |
| December 31, 2012 | 0.148M |
| September 30, 2012 | 94.69M |
| June 30, 2012 | 2.981M |
| March 31, 2012 | 1.917M |
| December 31, 2011 | 1.374M |
| September 30, 2011 | 0.716M |
| June 30, 2011 | 89.79M |
| March 31, 2011 | 0.441M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
0.039M
Minimum
Mar 2023
437.56M
Maximum
Jun 2023
58.42M
Average
1.366M
Median
Cash from Financing (Quarterly) Benchmarks
| AbbVie Inc | 10.82B |
| Pfizer Inc | -4.931B |
| Johnson & Johnson | 546.00M |
| Merck & Co Inc | -2.814B |
| Cerevel Therapeutics Holdings Inc | 4.475M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 2.77M |
| Cash from Investing (Quarterly) | -1.354M |
| Free Cash Flow | -199.78M |
| Free Cash Flow Per Share (Quarterly) | 0.0049 |
| Free Cash Flow to Equity (Quarterly) | 1.26M |
| Free Cash Flow to Firm (Quarterly) | 1.416M |